PASSAGE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-09-30 was 78.36K shares, a 185.86% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 31.93K shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 126.06K shares, a 14.12% decline from fiscal 2021.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 146.79K shares, a 47.11% increase from fiscal 2020.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 99.78K shares, a 90.01% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares S-4/A · filed 2026-09-03 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | 31.93K shares 10-K · filed 2025-03-04 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 126.06K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 78.36K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 198.03K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 147.08K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 47.70K shares 10-Q · filed 2022-05-16 | 184.08K shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 71.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 146.79K shares 10-K · filed 2022-03-03 |
| 2021-09-30 | 27.41K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 86.76K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 37.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 102.40K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 10.40K shares 10-Q · filed 2021-05-05 | |
| 2020-12-31 | 11.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | 99.78K shares 10-K · filed 2021-03-03 |
| 2020-09-30 | 43.06K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | |
| 2019-12-31 | 998.87K shares 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |